Chubb and VCT Forge Alliance to Overhaul Clinical Trial Risk

BOCA RATON, Fla. – April 28, 2026 – In a move poised to reshape risk management in clinical research, global insurance leader Chubb and Verified Clinical Trials (VCT), a pioneer in subject registry technology, have announced a strategic alliance. The partnership aims to directly confront foundational challenges in drug development by integrating VCT's real-time subject verification system with Chubb's extensive clinical trial insurance and risk management framework. This collaboration signals a significant shift in the industry, moving from a reactive model of insuring against failure to a proactive strategy designed to prevent it.

The alliance is designed to enhance research subject safety, improve the quality of trial data, and ultimately increase the likelihood of successful outcomes. By combining their respective expertise, the two companies are creating a new safeguard for the multi-billion dollar clinical research ecosystem, where the integrity of data and the well-being of participants are paramount.

A Proactive Shift in a High-Stakes Industry

The clinical trial landscape is in the midst of a profound transformation. As studies grow more complex and global in scale, the financial and scientific stakes have never been higher. The market for clinical trial technology and risk management services is booming, projected to exceed $60 billion by 2030 as the industry races to adopt digital tools, automation, and data-driven strategies. This partnership between an insurance titan and a specialized tech leader exemplifies this evolution.

Traditionally, risk management in clinical trials has relied heavily on insurance policies that provide a financial backstop in the event of adverse events or study failure. While essential, this approach is fundamentally reactive. The alliance with VCT allows Chubb, a leading underwriter of clinical trials for over two decades, to offer its clients a powerful preventative tool. This proactive layer of protection is designed to identify and mitigate risks at the earliest possible stage: the moment a potential participant is screened.

"Chubb is committed to supporting innovative and practical approaches to risk management in clinical research," said Lee Farrow, EVP and Life Sciences Industry Practice Leader at Chubb. This partnership reflects that commitment by integrating a solution that addresses a core operational vulnerability.

Confronting the Challenge of Duplicate Enrollment

A persistent and often underestimated threat to clinical research is the issue of duplicate enrollment. This occurs when individuals, sometimes referred to as "professional research subjects," enroll in multiple clinical trials simultaneously or without observing the required 'washout' period between studies. This practice poses a dual threat: it jeopardizes participant safety through potential adverse drug interactions and contaminates the study data, rendering it unreliable.

Traditional screening methods, which often rely on self-reporting and siloed site-specific databases, are frequently inadequate for detecting these violations. A participant can easily enroll in a trial at one site and then another sponsored by a different company across town or even in another country. This is the specific problem VCT was created to solve. Its proprietary global database provides a cross-sponsor, cross-study registry that can flag a duplicate enrollment in real time, regardless of the sponsor or location.

Farrow noted the significance of this capability, stating, "VCT addresses a longstanding and underrecognized challenge in clinical research: the inability to reliably look into a participant's research history to confirm eligibility." By preventing ineligible participants from enrolling, the system helps ensure that the collected data is clean and that subjects are not exposed to unnecessary risks.

The Business Case for Integrity

Beyond the critical ethical and scientific benefits, there is a powerful business case for bolstering trial integrity. The cost of bringing a new drug to market can exceed a billion dollars, and a failed trial represents a catastrophic loss of time and capital. Compromised data quality is a leading cause of study failure, leading to costly delays, additional trials, and potential rejection by regulatory bodies like the FDA.

This alliance provides tangible financial and operational advantages for sponsors, contract research organizations (CROs), and research sites. By reducing the incidence of protocol violations related to duplicate enrollment, the partnership helps:

• Mitigate Financial and Liability Risks: Fewer adverse events and cleaner data reduce the potential for costly liabilities and regulatory penalties.
• Improve Operational Efficiency: Preventing ineligible subjects from entering a study saves significant resources that would otherwise be spent on screening, enrollment, and data management for participants who would later be disqualified.
• Increase the Probability of Success: Reliable data strengthens the statistical power of a study, providing a clearer and more accurate assessment of a drug's safety and efficacy, which is fundamental to achieving research objectives and securing regulatory approval.

A Synergistic Alliance for a Safer Future

The strength of this partnership lies in the complementary nature of the two organizations. Chubb brings its global scale, deep underwriting expertise, and established relationships across the life sciences industry. VCT contributes its focused, best-in-class technology that is already trusted by a majority of top pharmaceutical companies and CROs.

"Research subject safety and data integrity are fundamental to every successful clinical trial," said Dr. Mitchell Efros, Co-Founder & CEO at Verified Clinical Trials. "This alliance with Chubb represents an important opportunity to help bring greater protection, stronger oversight, and added value to the clinical research ecosystem."

By integrating VCT's verification capabilities into a broader risk management context, the alliance creates a more secure and transparent environment for all stakeholders. It represents a meaningful evolution in how the industry approaches risk, as noted by Kerri Weingard, VCT's Co-Founder, VP, and Global COO. "This alliance with Chubb represents a meaningful advancement in how the industry approaches risk - moving from reactive to proactive safeguards," she stated. "By combining VCT's real-time subject verification capabilities with Chubb's global risk management expertise, we are helping to create a more secure, transparent, and reliable clinical trial ecosystem that ultimately benefits sponsors, sites, and, most importantly, patients."

Ultimately, this collaboration underscores a shared vision for the future of clinical research—one where technology and expert oversight converge to not only protect financial investments but to fundamentally safeguard human lives and the scientific process itself, helping to bring safer, more effective therapies to the public with greater confidence.